创新性的轨迹分析揭示了法国队列中肾移植后糖尿病的动态和危险因素

IF 1.9 4区 医学 Q2 SURGERY
Julie Olabe, Cyril Garrouste, Bruno Pereira, Charlotte Colosio, Antoine Thierry, Jean-Philippe Rerolle, Dominique Bertrand, Maïté Jaureguy, Léonard Goblin, Mathias Buchler, Yannick Le Meur, Valerie Chatelet, Jean-François Augusto, Igor Tauveron, Marie Batisse-Lignier, Anne Elizabeth Heng, ASTRE Study group
{"title":"创新性的轨迹分析揭示了法国队列中肾移植后糖尿病的动态和危险因素","authors":"Julie Olabe,&nbsp;Cyril Garrouste,&nbsp;Bruno Pereira,&nbsp;Charlotte Colosio,&nbsp;Antoine Thierry,&nbsp;Jean-Philippe Rerolle,&nbsp;Dominique Bertrand,&nbsp;Maïté Jaureguy,&nbsp;Léonard Goblin,&nbsp;Mathias Buchler,&nbsp;Yannick Le Meur,&nbsp;Valerie Chatelet,&nbsp;Jean-François Augusto,&nbsp;Igor Tauveron,&nbsp;Marie Batisse-Lignier,&nbsp;Anne Elizabeth Heng,&nbsp;ASTRE Study group","doi":"10.1111/ctr.70116","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Hypothesis</h3>\n \n <p>Post-transplant diabetes mellitus (PTDM) is a common, dynamic complication after kidney transplantation (KT) that may resolve over time. To better understand and prevent PTDM, we analyzed its prevalence, evolution, and influencing factors.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data from the French national ASTRE database at different post-transplantation periods (P) were analyzed. PTDM was defined by fasting blood glucose (FBG) ≥1.26 g/L, HbA1c ≥ 6.5%, or the use of hypoglycemic medications in kidney transplant recipients without diabetes. Patient trajectories were identified using group-based trajectory models (GBTM), and associated factors were examined.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 2898 patients, PTDM prevalence was 27.3% at P1 (&gt;M2, ≤M6), 21.3% at P2 (&gt;M6, ≤M18), 19.8% at P3 (&gt;M18, ≤M30), and 19.9% at P4 (&gt;M30, ≤M42). Analysis of 1825 patients identified four trajectories: no PTDM (67%), late-onset PTDM (6%), remission after P1 (10%), and early, persistent PTDM (17%). Late-onset PTDM was linked to history of cardiovascular disease, higher BMI at transplantation, HCV positive status, and weight gain. Early, persistent PTDM was associated with older age, higher BMI, HVC positive status, history of cardiovascular disease, and tacrolimus use. PTDM remission was linked to lower BMI. Corticosteroids contributed to both late-onset and persistent PTDM, while switching between tacrolimus and cyclosporine did not significantly affect progression.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study confirmed the high prevalence and dynamic nature of PTDM after transplantation, emphasizing the critical role of pretransplant cardiovascular disease, BMI, and early post-transplant weight gain in the onset or remission of PTDM.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 3","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Innovative Trajectory Analysis Reveals Dynamics and Risk Factors of Post-Kidney Transplant Diabetes Mellitus in a French Cohort\",\"authors\":\"Julie Olabe,&nbsp;Cyril Garrouste,&nbsp;Bruno Pereira,&nbsp;Charlotte Colosio,&nbsp;Antoine Thierry,&nbsp;Jean-Philippe Rerolle,&nbsp;Dominique Bertrand,&nbsp;Maïté Jaureguy,&nbsp;Léonard Goblin,&nbsp;Mathias Buchler,&nbsp;Yannick Le Meur,&nbsp;Valerie Chatelet,&nbsp;Jean-François Augusto,&nbsp;Igor Tauveron,&nbsp;Marie Batisse-Lignier,&nbsp;Anne Elizabeth Heng,&nbsp;ASTRE Study group\",\"doi\":\"10.1111/ctr.70116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Hypothesis</h3>\\n \\n <p>Post-transplant diabetes mellitus (PTDM) is a common, dynamic complication after kidney transplantation (KT) that may resolve over time. To better understand and prevent PTDM, we analyzed its prevalence, evolution, and influencing factors.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Data from the French national ASTRE database at different post-transplantation periods (P) were analyzed. PTDM was defined by fasting blood glucose (FBG) ≥1.26 g/L, HbA1c ≥ 6.5%, or the use of hypoglycemic medications in kidney transplant recipients without diabetes. Patient trajectories were identified using group-based trajectory models (GBTM), and associated factors were examined.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among 2898 patients, PTDM prevalence was 27.3% at P1 (&gt;M2, ≤M6), 21.3% at P2 (&gt;M6, ≤M18), 19.8% at P3 (&gt;M18, ≤M30), and 19.9% at P4 (&gt;M30, ≤M42). Analysis of 1825 patients identified four trajectories: no PTDM (67%), late-onset PTDM (6%), remission after P1 (10%), and early, persistent PTDM (17%). Late-onset PTDM was linked to history of cardiovascular disease, higher BMI at transplantation, HCV positive status, and weight gain. Early, persistent PTDM was associated with older age, higher BMI, HVC positive status, history of cardiovascular disease, and tacrolimus use. PTDM remission was linked to lower BMI. Corticosteroids contributed to both late-onset and persistent PTDM, while switching between tacrolimus and cyclosporine did not significantly affect progression.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study confirmed the high prevalence and dynamic nature of PTDM after transplantation, emphasizing the critical role of pretransplant cardiovascular disease, BMI, and early post-transplant weight gain in the onset or remission of PTDM.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 3\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70116\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70116","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

背景与假设:移植后糖尿病(PTDM)是肾移植术后常见的动态并发症,可能随着时间的推移而消退。为了更好地了解和预防PTDM,我们分析了其患病率、演变和影响因素。方法分析法国国家ASTRE数据库移植后不同时期(P)的数据。无糖尿病肾移植受者的空腹血糖(FBG)≥1.26 g/L, HbA1c≥6.5%,或使用降糖药物来定义PTDM。使用基于组的轨迹模型(GBTM)确定患者轨迹,并检查相关因素。结果2898例患者中,P1 (>M2,≤M6) PTDM患病率为27.3%,P2 (>M6,≤M18)为21.3%,P3 (>M18,≤M30)为19.8%,P4 (>M30,≤M42)为19.9%。对1825例患者的分析确定了四种轨迹:无PTDM(67%)、迟发性PTDM(6%)、P1后缓解(10%)和早期持续性PTDM(17%)。迟发性PTDM与心血管病史、移植时较高的BMI、HCV阳性状态和体重增加有关。早期、持续性PTDM与年龄较大、BMI较高、HVC阳性状态、心血管病史和他克莫司使用相关。PTDM缓解与较低的BMI有关。皮质类固醇导致迟发性和持续性PTDM,而他克莫司和环孢素之间的切换对进展没有显著影响。结论本研究证实了移植后PTDM的高患病率和动态性,强调了移植前心血管疾病、BMI和移植后早期体重增加在PTDM发病或缓解中的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Innovative Trajectory Analysis Reveals Dynamics and Risk Factors of Post-Kidney Transplant Diabetes Mellitus in a French Cohort

Background and Hypothesis

Post-transplant diabetes mellitus (PTDM) is a common, dynamic complication after kidney transplantation (KT) that may resolve over time. To better understand and prevent PTDM, we analyzed its prevalence, evolution, and influencing factors.

Methods

Data from the French national ASTRE database at different post-transplantation periods (P) were analyzed. PTDM was defined by fasting blood glucose (FBG) ≥1.26 g/L, HbA1c ≥ 6.5%, or the use of hypoglycemic medications in kidney transplant recipients without diabetes. Patient trajectories were identified using group-based trajectory models (GBTM), and associated factors were examined.

Results

Among 2898 patients, PTDM prevalence was 27.3% at P1 (>M2, ≤M6), 21.3% at P2 (>M6, ≤M18), 19.8% at P3 (>M18, ≤M30), and 19.9% at P4 (>M30, ≤M42). Analysis of 1825 patients identified four trajectories: no PTDM (67%), late-onset PTDM (6%), remission after P1 (10%), and early, persistent PTDM (17%). Late-onset PTDM was linked to history of cardiovascular disease, higher BMI at transplantation, HCV positive status, and weight gain. Early, persistent PTDM was associated with older age, higher BMI, HVC positive status, history of cardiovascular disease, and tacrolimus use. PTDM remission was linked to lower BMI. Corticosteroids contributed to both late-onset and persistent PTDM, while switching between tacrolimus and cyclosporine did not significantly affect progression.

Conclusion

This study confirmed the high prevalence and dynamic nature of PTDM after transplantation, emphasizing the critical role of pretransplant cardiovascular disease, BMI, and early post-transplant weight gain in the onset or remission of PTDM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Transplantation
Clinical Transplantation 医学-外科
CiteScore
3.70
自引率
4.80%
发文量
286
审稿时长
2 months
期刊介绍: Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信